Briacell Therapeutics Corp Stock Price, News & Analysis

BriaCell (Nasdaq: BCTX) will present clinical and preclinical data at the 2025 San Antonio Breast Cancer Symposium (SABCS), Dec 9–12, 2025. The company announced three clinical posters and one preclinical poster, including two late-breaking clinical posters reporting updated biomarker and survival data from its Phase 3 Bria-ABC trial and Phase 2 Bria-IMT study in metastatic breast cancer.

All posters are scheduled for Wednesday, Dec 10, 2025; poster copies will be available at https://briacell.com/scientific-publications/ after presentation.

BriaCell (Nasdaq: BCTX) is presenting preclinical evidence for its next‑generation Bria-OTS+ cancer immunotherapy platform at SITC 2025 (Nov 7–9, National Harbor, MD).

Poster Title: Redefining Cancer Vaccines: Bria-OTS+ Integrates Trained Innate Immunity and Adaptive Memory to Overcome Immune Resistance. Presentation times: Nov 7, 12:15–1:45 PM and 5:35–7:00 PM ET (Prince George ABC).

Key preclinical findings show rapid, potent and durable anti‑tumor activity driven by coordinated activation of innate and adaptive immunity; lead candidates Bria-BRES+ (breast) and Bria-PROS+ (prostate) demonstrated increased tumor cell cytotoxicity and broad platform applicability across multiple solid tumor models.

BriaCell (Nasdaq: BCTX) announced a poster at the Society for Immunotherapy of Cancer (SITC) 40th Annual Meeting on Nov 7, 2025 showing preclinical anti-cancer activity of its next-generation Bria-OTS+ platform. The poster (Abstract 353) will present immune activation and cytotoxicity data for lead candidates Bria-BRES+ (breast cancer) and Bria-PROS+ (prostate cancer).

The company reported completion of GMP manufacturing for planned clinical trials and a $2 million NCI SBIR award to support manufacturing and planned clinical evaluation of Bria-PROS+.

Poster sessions: Prince George ABC, Gaylord National Resort — 12:15–1:45 PM and 5:35–7:00 PM ET on Nov 7, 2025.

BriaCell (NASDAQ: BCTX) said an independent Data Safety Monitoring Board issued its fourth consecutive positive recommendation after reviewing safety data from the pivotal Phase 3 study of Bria-IMT plus immune checkpoint inhibitor in metastatic breast cancer (NCT06072612). The DSMB identified no safety concerns and recommended the study continue without modifications. The study is conducted under FDA Fast Track designation. DSMB meetings occur quarterly; this is the fourth positive quarterly review. Management highlighted confidence in the regimen's safety and tolerability and reiterated commitment to advancing the trial for patients with urgent unmet needs.

BriaCell (Nasdaq: BCTX) added Dartmouth Cancer Center, Cedars-Sinai Medical Center, and Winship Cancer Institute of Emory University to its pivotal Phase 3 metastatic breast cancer study (ClinicalTrials.gov NCT06072612).

The trial now has 79 clinical sites across 23 US states enrolling patients and evaluates Bria-IMT plus an immune checkpoint inhibitor versus physician’s choice. Interim analysis is planned once 144 patient events (deaths) occur, and the company anticipates reporting top-line data as early as H1-2026. The Bria-IMT regimen holds FDA Fast Track designation.

BriaCell (Nasdaq: BCTX) announced a collaboration with Memorial Sloan Kettering Cancer Center's Therapeutics Accelerator to support the development of Bria-OTS+, including Bria-BRES+ for metastatic breast cancer, on October 21, 2025. The agreement covers manufacturing, IND preparation and clinical protocol support aimed at enabling a Phase 1 clinical trial.

The partnership gives BriaCell access to MSK’s institutional expertise in cell therapy manufacturing and clinical development to expedite Bria-OTS+ advancement into the clinic.

BriaCell (Nasdaq: BCTX) presented biomarker data from its ongoing pivotal Phase 3 trial of Bria-IMT plus an immune checkpoint inhibitor in metastatic breast cancer at ESMO 2025 (poster #3928).

Pooled, blinded data from 113 patients (median 6 prior lines) show biomarker trends consistent with Phase 2: neutrophil-to-lymphocyte ratio (NLR) remains a potential predictor of clinical benefit (Phase 2 PFS 4.5 vs 2.5 months; HR 0.5, 95% CI 0.3–0.8, p=0.005). No new safety or tolerability signals were identified and there were no treatment-related discontinuations.

Interim OS analysis is planned at 144 events. Bria-IMT combination has FDA Fast Track designation.

BriaCell (Nasdaq: BCTX) will present positive clinical biomarker data from its ongoing pivotal Phase 3 BRIA-ABC study of Bria-IMT plus an immune checkpoint inhibitor in metastatic breast cancer at ESMO 2025 on Oct 20, 2025.

In a blinded analysis of 68 evaluable patients (median 6 prior lines), patients who developed a positive delayed-type hypersensitivity (DTH) response showed a significant improvement in progression-free survival (p=0.0002). No new safety or tolerability issues were identified; common AEs: fatigue 22.8%, anemia 22.8%, nausea 21.5%.

Primary OS interim analysis will occur at 144 patient deaths; Bria-IMT has FDA Fast Track designation.

BriaCell (Nasdaq: BCTX) will present preclinical data for Bria-OTS+ at the Society for Immunotherapy of Cancer (SITC) 40th Anniversary Annual Meeting, November 7-9, 2025, in National Harbor, MD.

Presentation details: Title "Redefining Cancer Vaccines: Bria-OTS+ Integrates Trained Innate Immunity and Adaptive Memory to Overcome Immune Resistance"; Abstract No. 353; Location Prince George ABC Exhibit Halls, Gaylord National Resort and Convention Center; Date Friday, Nov. 7, 2025. Poster will be posted after the meeting at https://briacell.com/scientific-publications/.